Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chemotherapy
100%
Lung Squamous Cell Carcinoma
100%
Synergize
100%
Chemoimmunotherapy
100%
Anti-programmed death-1
80%
Immune Checkpoint Inhibitors
60%
Programmed Death-ligand 1 (PD-L1)
40%
Tertiary Lymphoid Structures
40%
Gut Microbiota Composition
40%
Anti-PD-1 Monoclonal Antibody
40%
Maximum Tolerated Dose Chemotherapy
40%
Tumor
20%
Maximum Tolerated Dose
20%
Peripheral Blood Mononuclear Cells
20%
Survival Benefit
20%
Molecular Mechanism
20%
Transcription Factor
20%
Possible Mechanisms
20%
Syngeneic
20%
Therapeutic Target
20%
Clinical Trials
20%
Macrophages
20%
Antitumor
20%
Dendritic Cells
20%
Antigen Presentation
20%
Immunomodulatory Effect
20%
Immune Memory
20%
Nuclear factor-κB Pathway
20%
Systemic Immune Response
20%
Metronomic Chemotherapy
20%
Combined Method
20%
Antigen Exposure
20%
Antigen Uptake
20%
Dendritic Cell Activation
20%
Current Clinical Practice
20%
Low-dose Chemotherapy
20%
Cytotoxic CD8+ T Cells
20%
PD-L1 Expression
20%
Intestinal Gut
20%
Programmed Cell Death Protein 1 (PD-1)
20%
Immunocompetent Mouse Model
20%
Phosphatidylinositol 3-kinase/Akt
20%
Specific T Cell Response
20%
Response Memory
20%
Immunology and Microbiology
Squamous Cell
100%
Immunotherapy
100%
Lung
100%
Programmed Death-Ligand 1
80%
Maximum Tolerated Dose
60%
Immune Checkpoint Inhibitor
60%
Monoclonal Antibody
40%
Dendritic Cell
40%
Low Drug Dose
40%
Cell Line
20%
Cytotoxic T-Cell
20%
T Cell
20%
Transcription Factor
20%
Mouse Model
20%
Immune Response
20%
Macrophage
20%
Peripheral Blood Mononuclear Cell
20%
Intestine Flora
20%
Syngenic
20%
Signal Transduction
20%
Antigen Presentation
20%
Programmed Death 1 Ligand 1
20%
Immunoglobulin Enhancer Binding Protein
20%
Immunological Memory
20%
Antigen
20%
Phosphotransferase
20%
Kinase
20%
Therapeutic Target
20%